NCT05652283

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

An Exploratory Clinical Study of Neoadjuvant Therapy With Pamiparib Combined With Surufatinib for Advanced Ovarian Cancer: A Single-arm, Prospective, Single-center Clinical Study

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (estimated)
• Sponsor: Bai-Rong Xia · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this type of clinical trial study is to evaluate the safety and efficacy of Pamiparib combined with Surufatinib as a new neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer.

Detailed description

Patients will have tests and exams to see if they are eligible for the clinical trial. If found eligible, the patient will receive Pamiparib twice daily and Surufatinib once daily taken by mouth every 3 weeks. Patients who had no progression after neoadjuvant therapy were treated with surgery, and 4 cycles of chemotherapy were given after surgery.

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Pamiparib	Pamiparib capsule 40 mg/time, twice a day, oral, 3 weeks as a cycle, 3 cycles
DRUG	Surufatinib	Surufatinib 250 mg/time, once a day, oral, 3 weeks as a cycle, 2 cycles

Timeline

• Start date: 2022-11-06
• Primary completion: 2024-05-31
• Completion: 2026-05-01
• First posted: 2022-12-15
• Last updated: 2024-11-27

Locations

1 site across 1 country: China